• Provides access through bank partners to secure online, safe and convenient banking services for businesses in the cash-intensive cannabis industry
• Founded by banking and payments industry veterans experienced in building and scaling businesses
• Partnered with numerous financial institutions to help cash-intensive businesses reduce financial and safety risk, and run their businesses more efficiently
• Deposits held at partner banks are FDIC-insured up to $250,000 per account

Dama Financial, through its bank partners, provides cannabis-related businesses (CRBs) access to transparent, sustainable banking and payment solutions. Using innovative technology, data and artificial intelligence, Dama exceeds the compliance and regulatory requirements for servicing CRBs, bringing legitimacy to the rapidly growing cannabis industry. Dama’s comprehensive and compliant financial framework offers CRBs the option to maintain cashless operations, reducing their exposure to security risks while improving their business efficiencies and operational focus.

Background

As successful fintech entrepreneurs, Dama’s founders have a proven track record of building companies that have removed the barriers that exclude unbanked categories from accessing the fundamental financial solutions necessary to thrive. During the past three years, Dama’s leadership team has turned its focus to addressing the challenges burdening the cannabis industry – the unbanked category of our time.

On behalf of its bank partners, Dama offers access to:

Dama Premier

• Schedule recurring or ad-hoc appointments for secure cash pick-ups and delivery via armored courier
• Monitor activity in real time via desktop or mobile or be notified of transaction alerts via email or text
• Send payments via electronic ACH, wire-transfer or check to approved payees
• Receive electronic funds from approved partners
• Transfer money quickly between Dama-managed accounts

CashToTax℠

• Schedule secure cash pick-ups and delivery via armored courier
• Monitor activity in real time via desktop or mobile or be notified of transaction alerts via email or text
• Send electronic tax payments to approved tax authorities
• Monitor account activity 24/7 with online and mobile access
• No minimum balance or account fees

PayMyWay℠

• Accept electronic retail payments using the secure PayMyWay℠ mobile application
• Customers can fund the app using a linked bank account or debit card at checkout with any PayMyWay merchant
• Funds settle to the merchant’s PayMyWay Merchant account
• Integrates seamlessly with any point-of-sale system

All Dama clients enjoy:

• FDIC insurance on deposits of up to $250,000 per account
• Dedicated Relationship Manager for account-related inquiries

Dama Financial is an agent of its partnering financial institutions and licensed money transmitters. Customers’ funds will be deposited into a custodial account maintained for the benefit of account holders at one or more FDIC-insured institutions. Fees, terms and conditions apply to depositing funds into and using an Account. Account Terms and Conditions and Fee Schedule are available upon registration to access the online application.

For more information, visit the company’s website at www.DamaFinancial.com

NOTE TO INVESTORS: The latest news and updates relating to Dama Financial are available in the company’s newsroom at http://ibn.fm/Dama

• VPR Brands focuses on the cannabis and nicotine industries
• The company is shifting initiatives toward cannabidiol (CBD)
• VPR Brands focuses on premier products and distribution in order to build sales and profits

CBD products in an array of forms continue to transform the marketplace, surpassing Kim Kardashian, Beyoncé, and veganism in search popularity according to Google data (http://ibn.fm/rpYXZ). CBD is on the rise as one of the most popular terms searched, as consumers are continually looking for unique, high-quality CBD products and the enterprises that manufacture and distribute them. The forecast calls for the CBD market to grow to an estimated $22 billion by 2022 (http://ibn.fm/mPFDs).

A technology holding company, VPR Brands LP (OTCQB: VPRB) is positioned at the juncture of the cannabis and nicotine industries and poised to take advantage of the steady growth of CBD popularity. The company’s assets include issued U.S. and Chinese patents for atomization-related products, including technology for medical marijuana vaporizers and electronic cigarette products and components. One of the most undervalued, unknown gems on the OTC Markets in the cannabis sector, VPRB additionally is involved in product development for up-and-coming innovations poised to disrupt in various markets.

Based in Fort Lauderdale, Florida, VPR Brands is shifting its emphasis toward CBD (cannabidiol) as it prepares to launch two new CBD brands websites: www.DrGoodHemp.com and www.CBDBrandDepot.com. With its strong strategy of continually adding quality products and distribution designed to grow sales, VPR’s increasing customer base portends well for its CBD initiatives as the company offers a diverse portfolio of innovative products.

VPR Brands nurtures brands by way of direct sales and licensing opportunities in the CBD vertical. The company’s in-house product development is a significant differentiator, allowing VPRB to expand its margins (http://ibn.fm/oOaoT). VPR’s flagship CBD line, GoldLine, provides a broad product portfolio with offerings that include pre-rolled joints, vape cartridges, edibles, CBD pens, and crumble as well as tinctures.

VPR Brands, with its astute management team leading the way, is well positioned to leverage this burgeoning market. The company’s diverse brand portfolio includes GoldLine, GoldLine Hemp, HoneyStick, Helium, Vaporin, and Vaporx. VPRB also has its Vapor Store Direct in Fort Lauderdale, which is one of the largest vaporizer and e-liquid wholesalers in the United States. Regarding CBD specifically, VPR Brands’ GoldLine is at the forefront of the market when it comes to pioneering safe, all-natural CBD-derived products.

VPR Brands’ emphasis on first-rate products, widespread distribution, and an engaged customer base offers ROI potential for investors looking to participate in CBD initiatives. By combining premium ingredients and extracts coupled with modern technology, the company’s GoldLine brand offers the ultimate selection of CBD and hemp-based products available in the marketplace.

Furthermore, VPR Brands knows how to efficiently market its product family for revenue growth and will bring this expertise to its CBD program. Of note is VPRB’s stellar performance. The company increased its Q1 2019 revenues roughly 31 percent year over year to $1.3 million. In addition, VPRB continues to maintain strong gross operating margins above 40 percent (http://ibn.fm/yFFmQ). Concerning its 2018 results, VPR Brands increased its full-year revenues to roughly $4.6 million while its full-year 2018 gross operating margins increased by close to 20 percent from 2017 to a margin of 41 percent in 2018 (http://ibn.fm/KoyoU).

As VPR Brands continues to concentrate on cannabis consumables and market-share growth, that upward trend will likely only increase. The company partners with leading global brands to elevate and accelerate its products into the vanguard of the industry. VPR Brands offers investors the opportunity for portfolio diversification with its dynamic suite of brands for the nicotine and CBD markets.

For more information, visit the company’s website at www.VPRBrands.com

NOTE TO INVESTORS: The latest news and updates relating to VPRB are available in the company’s newsroom at http://ibn.fm/VPRB

• IONIC Brands Corp. is a west coast company which was established in 2015 as a supplier of recreational cannabis products such as cannabis oils and vaporizer products, including vape pens
• IONIC Brands Corp. achieved a year-over-year increase in revenue of over 377 percent, and it plans to expand into more states across the nation
• IONIC expects that, by early 2020, its products will be distributed through 318 stores in California and 225 stores in Oregon

IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) (FRA: IB3) is a cannabis holding company supplying recreational cannabis products, with headquarters in Tacoma, Washington. The company’s cannabis products are currently sold in 685 stores across the U.S., and it is planning further expansion around the country. In addition to other states, IONIC plans to expand to at least 318 stores in California and 225 stores in Oregon by January 2020.

This company offers luxury brands in the premium space and is involved in the recreational cannabis market. IONIC Brands was founded in 2015 by a group of entrepreneurs who were interested in the cannabis market. The company now focuses on making small batch cannabis oils and various cannabis concentrates that are pure and therefore do not contain any additives, additional glycols or glycerin chemicals. The vision behind IONIC Brands was to create products for the upscale recreational cannabis market. The cannabis market is predicted to expand in the future, particularly as legislation continues to evolve.

IONIC Brands Corp. has shown profits and increasing revenue over the last three years, and it aims to continue riding the strong performance of the cannabis space moving forward. Demand for concentrates is projected to increase in the future, and IONIC Brands believes that this provides an opportunity for growth.

The flagship product for IONIC is its vape pen line, which has done well in the marketplace, particularly in Washington State. This vaporizer product is currently ranked in the top 10 of such products in Washington State, which suggests that expansion into other states and distribution centers will likely be successful. Overall, vape sales grew by 93 percent in 2017 alone, and spending on edible cannabis products is projected to double from 2019 to 2022, reaching $4.1 billion.

IONIC Brands also has a certified clean program – which ensures that its products are clean in the sense that they pass states’ mandates for pesticide levels and safety. The company remains committed to ensuring safety and purity standards when producing its offerings.

The items and brands produced by IONIC include more than just the IONIC vaporizer pens; they also include Vuber technologies, Zoots edibles and Vegas M Stick vaporizer pens. The increasing popularity of these products is expected to lead to market growth for IONIC, which seeks to become a marketplace leader in the premium recreational cannabis industry.

IONIC Brands expects to add to its profits in the coming months, with revenue predicted to hit $46 million in 2019. Second quarter earnings for IONIC Brands showed an increase of over 377 percent year-over-year (http://ibn.fm/08vL3). The company leverages an aggressive growth strategy, is vertically integrated and has diversified its product range.

IONIC Brands has plans to be a national leader in the recreational cannabis space for both vaporizer products and edibles, and it also has ambitious expansion plans for the coming years and is interested in looking into markets outside of its current distribution network.

The company also made strides by recently acquiring patents for cannabinoid-infused coffee. With the popularity of coffee and cannabis, this is expected to be a good combination and investment for IONIC Brands in the coming years.

IONIC Brands’ portfolio includes ZOOTS, an edibles company that is also based in Washington, as well as Vegas Valley Growers based in Nevada and Vegas M stick pens. Through the Vegas M stick pens brand, IONIC plans to expand further into Nevada and Oregon; the products are currently distributed in Washington.

The market growth of the company and rising profits suggests that IONIC Brands will be able to successfully expand nationwide and further distribute its products throughout the nation. IONIC vape pen sales rose from just over $2 million in 2016 to $9.9 million in 2018, and, with the increasing popularity of vape pens, the trend seems likely to continue.

For more information, visit the company’s website at www.IONIC.social

NOTE TO INVESTORS: The latest news and updates relating to IONKF are available in the company’s newsroom at http://ibn.fm/IONKF

• As consumers have become increasingly health conscious as a fitness-interested segment of society, holistic-oriented wellness products have gained a parallel footing as alternatives to prescription drugs
• The trend is exemplified by the recent explosion of interest in cannabis-based products that don’t have marijuana’s drug qualities but do have muscle pain and spasm relieving properties
• Neutra Corp is preparing to introduce a transdermal pain-relief cream based on a CBD formulation designed to benefit athletes whose workouts induce aches and pains
• The CBD market is expected to top $1 billion in sales by 2022, a result of the growing interest and opportunity surrounding the market

Healthy living solutions research and development company Neutra Corp (OTCQB: NTRR) is preparing for the market release of a new transdermal, hemp-based sports cream designed to provide pain relief for amateur athletes and others involved in activities that require strenuous performance.

The cream rollout is the latest product to market created under Neutra’s subsidiary VIVIS Corp., an emerging retail brand of hemp-based health and nutritional products acquired last month as Neutra’s retail presence. Vivis has a line of products that feature a 99 percent or higher grade of hemp-extracted crystalline CBD, and a second product line in the works will feature an 80 percent or higher grade of full-spectrum CBD extract.

“We’re now seeing the positive payoff of hiring a dedicated sports medicine advisor earlier this year,” CEO Sydney Jim stated in a news release about the sports cream development (http://ibn.fm/iazNa). “Our goal with that hire was to develop hemp-based CBD (cannabidiol) products geared to the expanding sports market. VIVIS’ upcoming transdermal sports cream will appeal to the rapidly growing number of active Americans wanting to improve performance, relieve aches and pains, prevent injuries and lead healthier lifestyles.”

All of Vivis’ CBD products are tested and certified by a third party to ensure their purity.

Neutra began as a company interested in presenting all-natural and organic-based products to market in 2011 to help the human body’s ability to heal and regulate itself. The company has been finding a niche in the CBD-based market this year, contemplating the industry forecasts for a rapidly growing billion dollar revenue stream in the United States alone by 2022 (http://ibn.fm/hzoyi).

“In 2019 we’re really looking at trying to figure out how to participate in the hemp-based CBD market,” Jim said as part of an interview he had recently with NetworkNewsAudio (http://ibn.fm/qQbyX). “Our overall goal is to become a vertically integrated company from cultivation to manufacturing to formulation of products and then to distribution and retail sales.”

The CBD market is a subset of the cannabis industry, which has seen an explosion in interest during recent years that has driven legislative changes and a rebirth of valuation for the plant once common in the country’s agricultural circles before it was banned as a drug product labeled as having no practical use.

Hemp-derived CBD, often equated with medical marijuana, has gained widespread popularity as a home remedy for dealing with muscle pains and spasms. Neutra cites U.S. Department of Labor statistics indicating some 66 million people across the country are playing some sort of sport or exercising on any given day, accompanied by Johns Hopkins University research noting most athletics-caused discomforts can be treated through simple means such as creams and topicals.

For more information, visit the company’s website at www.NeutraInc.com

NOTE TO INVESTORS: The latest news and updates relating to NTRR are available in the company’s newsroom at http://ibn.fm/NTRR

• POAI recently announced the sale of 10 FDA-approved, CE-marked STREAMWAY Systems
• STREAMWAY Systems are the first truly continuous, direct-to drain fluid-disposal solutions designed specifically for medical applications
• The announcement is another positive indication that POAI subsidiary Skyline Medical offers tremendous qualitative, long-term potential

In a significant announcement that bodes well for the company, Predictive Oncology Inc. (NASDAQ: POAI) announced that its Skyline Medical Division, producer of the STREAMWAY(R) System, has completed the sale of 10 systems to a major New York hospital (http://ibn.fm/dXHwp). The sale exceeds POAI’s largest single-hospital sale to date, and it is anticipated that the systems collectively will handle 6,000 procedures every year.

The revolutionary FDA-approved, CE-marked STREAMWAY System is the first truly continuous, direct-to drain, fluid-disposal system designed specifically for medical applications such as radiology, endoscopy, surgery, urology and cystoscopy procedures.

STREAMWAY is transforming the way healthcare facilities process and handle potentially infectious waste. The innovative system connects directly to a facility’s plumbing system in order to automate the collection, measurement and disposal of waste fluids. This proprietary approach minimizes human intervention, creates a safer system, and provides improved compliancy with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines (http://ibn.fm/O0FzQ).

Moreover, because the STREAMWAY system doesn’t require canisters and evacuated bottles for collection purposes, it eliminates approximately 50 million potentially disease-infected canisters that wind up in landfills around the country. In addition to the positive environmental impact, the system also reduces overhead costs.

For Predictive Oncology, this announcement represents a significant financial milestone. As POAI’s largest single-hospital transaction ever, the sale indicates the credibility and trust the STREAMWAY System is building within the industry. In addition, the sale is another positive indication that Skyline Medical, a POAI subsidiary, provides tremendous qualitative, long-term potential as it continues to focus on and develop innovative and revolutionary technology and alternatives. Through its STREAMWAY System, Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Predictive Oncology operates in two business areas: first, applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for patients and clinicians as well as clients in the pharmaceutical, diagnostic, and biotech industries; and second, production of the STREAMWAY System through Skyline Medical.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, announced that final study results of a 2018 clinical study evaluating the use of its proprietary drug-delivery system have been published (http://ibn.fm/AYzRL) (http://ibn.fm/PfnAA). Published in Advances in Therapy, a peer-reviewed medical journal, the human clinical study evaluated CBD delivery and effectiveness using LXRP-patented, DehydraTECH(TM)-powered TurboCBD(TM) capsules.

Key findings highlighted in the publication included the following:

• CBD in-plasma levels with the TurboCBD 90 mg dose were significantly higher than with the generic 90 mg dose at both 90 and 120 minutes (p < 0.05);
• Only the TurboCBD 90 mg dose was elevated (i.e., greater than placebo) at 30 minutes (p < 0.05) and remained elevated (i.e., greater than placebo) at 4 hours (p < 0.01);
• Mean arterial blood pressure (MAP) in a subgroup analysis was significantly decreased with only the TurboCBD 90 mg dose relative to baseline (p < 0.05); and
• Cerebral perfusion analyzed by an index of conductance in the middle cerebral artery (MCA) in this subgroup was significantly higher with only the TurboCBD 90 mg dose relative to baseline (p < 0.001).

The key study was conducted and well tolerated in a dozen healthy young male athletes, with researchers concluded that additional studies were called for. Specifically, the report notes that “further acute and chronic dosing investigations in older and cerebrovascular-compromised patients may shed light on the vascular and clinical impacts of increased CBD bioavailability.”

Already the owner of more than 60 patent applications worldwide, Lexaria was recently granted two patents for “treating certain conditions including but not limited to heart disease, neurological diseases such as Alzheimer’s, Parkinson’s, schizophrenia” and others. The key findings from this most recent study may prove timely, considering the demonstrated effectiveness of DehydraTECH technology in increasing cerebral blood flow and perhaps providing increased efficiency at delivering certain drugs to the brain.

In its report, Advances in Therapy also referenced a second study published recently by a separate group of researchers that evaluated a comparable CBD dose with bioabsorption findings representative of the cannabinoid edibles industry sector in general. The results indicate that the rate of bioabsorption of the CBD from the competitive 100 mg formulation was virtually nondetectable within 30 minutes of administration, whereas the TurboCBD 90 mg dose delivered as much drug at 30 minutes as the competitor formulation required nearly 2.5 hours to achieve

Lexaria’s DehydraTECH drug-delivery technology improves the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and more than 60 patents pending worldwide.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at  http://ibn.fm/LXRP

• ORHub, a Microsoft Silver Partner, leverages the Azure cloud to help perioperative leaders unlock the power of health care data captured in the operating room
• Surgical Spotlight®, a cloud-based analytics tool, helps spot trends and outliers with curated performance indicators, increasing efficiency, decreasing costs and improving patient access in the operating room
• The global health care analytics market is projected to reach $50 billion by 2024, with a five-year CAGR of 28.3 percent from 2019
• Chief Executive Officer Dr. Robert ‘Bobby’ Lazzara is a renowned cardiac surgeon and founder of Medical News Minute

ORHub Inc. (OTC: ORHB), a cloud-based health care analytics company on a mission to optimize the business of surgery through lean process improvement, offers a quick look at a simple solution to the complex nature of improving health care in an educational video presented by Chief Executive Officer Dr. Robert ‘Bobby’ Lazzara. Featuring one compelling aspect of ORHub’s analytics product, Surgical Spotlight®, Lazzara describes how state of the art solutions are created with Surgical Results data generated through real-time analytics.

“Behaviors that can center focus on team building and the development of surgical systems is approaching hospital systems nationwide, saving millions of dollars in improved patient access, all at the same time,” Lazzara stated in a news release announcing the video (http://ibn.fm/yeOLB).

Perioperative leadership who are currently hindered by archaic technical systems and burdened with monthly or quarterly reports can quickly envision the benefits of receiving daily reports that harness procedural costs, Lazzara stated. Millions of dollars in improved patient access, greater team building opportunities and improved business decisions can accurately be visualized and acted upon by utilizing real-time data received from ORHub’s Surgical Spotlight®.

Lazzara is a distinguished cardiac surgeon and Medical News Minute founder with a special interest in implementing the latest technology to serve the health care industry. Lazzara performed the first worldwide webcast of open-heart surgery in August 1998 through the Virtual Operating Room and, subsequently, MDiTV, Inc. broadcast the first live cardiac surgery over a smartphone on Dec. 15, 2009. He is a Smithsonian Laureate for his pioneering work utilizing the internet and information technology as a health care educational tool.

“Of dozens of facilities I’ve operated in throughout our country and worldwide, there has been no other comprehensive data system on the market that compares,” Lazzara said of ORHub’s Surgical Spotlight® (http://ibn.fm/S35uI). “Being able to truly understand our cost and care decisions will heighten the level of cost-effective patient care and optimize the overall efficiency for our entire health care system.”

In an exclusive interview with NetworkNewsWire, Lazzara stated the company’s focus revolves around becoming a powerful foundational resource in the operating room (http://ibn.fm/XM0gy).

“By providing the information that allows for a change in behavior, control is put into the hands of surgeons and administrators, enabling the evaluation of trends, and empowering the facility to make instantaneous adjustments that will continue building efficiency and profitability on an ongoing basis,” Lazzara added.

The U.S. surgical market continues to grow with over 5,500 hospitals and 6,100 ambulatory surgery centers performing over 50 million medical procedures annually. The global health care analytics market is projected to be valued at more than $50 billion by 2024, growing at a compound annual growth rate of 28.3 percent from 2019 to 2024, according to MarketsandMarkets (http://ibn.fm/PRN5f).

For more information, visit the company’s website at www.ORHub.com

NOTE TO INVESTORS: The latest news and updates relating to ORHB are available in the company’s newsroom at http://ibn.fm/ORHUB

• POAI is leveraging the potential of AI and smart tumor profiling to predict tumor drug response
• TumorGenesis is developing innovative techniques for growing tumors in laboratory settings
• Helomics uses vital information from patients’ own living tumors to assist oncologists in selecting the most effective treatments

Predictive Oncology Inc. (NASDAQ: POAI) is harnessing the power of artificial intelligence (AI) and rich information from patients’ own tumors to improve outcomes for cancer patients. Predictive Oncology applies its proprietary smart tumor profiling and AI platform to extensive genomic and biomarker patient datasets in order to predict tumor drug response and improve clinical outcomes for cancer patients.

Last year, POAI, then known as Precision Therapeutics, formed TumorGenesis to focus on innovative ways to create improved patient derived (PDx) tumor models. Currently, TumorGenesis is working on developing new techniques for growing tumors in the lab to generate more relevant models of the tumors that can be used to test drugs for personalized therapy or aid in development of new medications.

The approach is designed to grow tumors in the lab by providing an environment that closely mimics the human body, through the use of chemistry, biology, mechanics and cell nutrients. In addition to this exclusive technology being quicker and more affordable than existing PDx animal models, researchers anticipate that the approach will better replicate the characteristics of tumors. Initially, the company plans to develop PDx models for multiple myeloma, triple-negative breast cancer and ovarian cancer, but Predictive is expecting the technology to ultimately benefit oncologists who are investigating other cancer areas as well, including liver, pancreatic, lung and colon.

To validate these new tumor models, TumorGenesis is working closely with Predictive’s Helomics team and is also actively looking for external partners that could potentially benefit from these innovative technologies and advance research.

Helomics is dedicated to improving the standard of care for cancer patients by using vital information provided by patients’ own living tumors to assist oncologists in selecting the most effective treatments. Helomics uses its exclusive tumor drug-response profiling platform, together with the latest next-generation sequencing (NGS)-based genomic profiling and its vast knowledgebase of 150,000 tumors, to provide additional context to create a valuable predictive tool for clinicians and researchers. This approach is rooted in the company’s belief that capturing this invaluable patient-specific information in conjunction with such a huge historical database provides a more functional approach to precision medicine than relying on genomics alone.

In a page straight out of Sun Tzu’s The Art of War, Predictive Oncology is helping oncologists and researchers “know the enemy” by harnessing rich information from patient tumors using artificial intelligence to build predictive models of tumor drug response. Predictive Oncology is working with the pharmaceutical, diagnostic and biotech industries to use these models to both improve the development of new drugs and help clinicians individualize therapy. For investors, Predictive Oncology offers the possibility for significant ROI, as it has already amassed (through its acquisition of Helomics) a huge cancer dataset that can be mined to provide valuable insights to improve treatment.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• More than 125 direct-selling experts met with members of Congress to encourage support of the Preserving the Direct Seller Independence Act
• Flexibility is a driving force behind individuals becoming direct sellers
• SHRG focuses on elevating the lives of its Elepreneurs through its superior products and services

On September 18, more than 125 executives and independent direct sellers gathered on Capitol Hill to represent 19 Direct Selling Association (DSA) member businesses and over six million entrepreneurs. Participants met with members of Congress to support the passage of H.R. 3522 (http://ibn.fm/g3vbT), the Preserving the Direct Seller Independence Act. Together, they emphasized the importance of protecting independent workers and discussed the benefits direct selling has brought to millions of Americans. Participants spoke with nearly 100 Congress members, urging them to maintain the independent contractor status for all direct sellers. Sharing Services Global Corporation (OTCQB: SHRG), a diversified holdings company, is working to elevate these home-based entrepreneurs.

“As we see more people choosing independent work in today’s economy, it’s important that we recognize that all independent work is not the same,” DSA President and CEO Joseph N. Mariano stated in a Direct Selling News article (http://ibn.fm/G7EWK). “Choice is a critical distinction to make, and H.R. 3522 preserves direct sellers’ ability to choose the products they want to sell, the customers they engage with, and the hours they will work – and make those decisions based on their own needs, responsibilities, and aspirations.”

SHRG provides independent direct sellers with the resources necessary to succeed in the quickly growing global direct-sales market.

SHRG offers a wide range of products and services in the health and wellness area. Using what it calls the Blue Ocean Strategy, the company focuses on three main components: elevating home-based entrepreneurs, generating organic growth and creating independent business leaders.

The 2019 DSA National Salesforce Study identified flexibility as the driving force behind individuals choosing to become direct sellers. Elepreneurs, SHRG’s coined term for independent representatives, find freedom through much-needed services and features that other direct-selling companies often lack. Elepreneurs LLC is a wholly owned subsidiary of SHRG that offers and sells health and wellness products through the direct-selling model.

SHRG focuses on elevating the lives of its independent sales representatives through a variety of products and services. Sharing Services has created a flexible business model that encourages goal setting for health to enhance the happiness of its independent representatives. SHRG is on a mission to serve others, promote happiness, encourage healthier lifestyles and redefine what it means to be wealthy. Those who desire the flexible, independent lifestyles found in direct selling through SHRG gain access to inspiring seminars, classes and workshops that provide training in every area necessary to assist them in being successful.

Even Sharing Service’s product line, Elevacity, is formulated to increase happiness and health. Harvard University has been studying happiness since 1938, and SHRG has paid attention to the university’s findings: Success does not fuel happiness, happiness fuels success. Elevacity Global LLC’s product line is designed to elevate mood, create connection, increase energy and provide focus and clarity. The comprehensive training the company provides for its Elepreneurs isn’t the only thing that sets SHRG apart; the company’s commitment to elevate the lives of all who come in contact with Sharing Services creates a distinct difference. Happiness, flexibility and independence are at the heart of everything Sharing Services offers.

Headquartered out of a 10,000-square-foot facility in Plano, Texas, SHRG has planned for future expansion. Customer-service facilities, operations and training rooms, and a video-production suite are currently available onsite, with room for growth in each area. In addition, SHRG is looking forward to international expansion. The Elevacity line of products is currently available in the United States, Canada, New Zealand and Australia.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at  http://ibn.fm/SHRG

• Lexaria Bioscience is helping to revolutionize efforts to provide common drug substances in an ingestible method that avoids unhealthy practices such as inhaled smoking or vaping
• Lexaria’s DehydraTECH platform works to deliver the chemical compounds to the blood stream at speeds comparable to inhalation methods, providing the means for discrete use and avoiding frustrating waits for users with dependencies
• The company recently obtained a patent in Australia that recognizes DehydraTECH not only as a food and beverage platform, but also as a potential means of pharmaceutical use for combatting select illnesses
• As Canada prepares to introduce legalization of cannabis food and beverage products next month, analysts forecast a market worth $2.7 billion a year for edibles and alternative cannabis products, with extract products including edibles comprising 60 percent of the total

As Canada prepares to roll out its ‘Cannabis 2.0’ wave of product legalization focused on edible and drinkable forms of the plant’s core ingredients less than a month from now, with the products themselves hitting store shelves beginning in December, analysts are anticipating a consumables market rife with opportunity for innovation. Deloitte predicts the Canadian market for edibles and alternative cannabis products alone will be worth $2.7 billion annually, and that cannabis extract-based products including edibles will make up nearly 60 percent of that amount at $1.6 billion (http://ibn.fm/pxHkr).

Bioactive technology innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is preparing to make its presence known in this new marketplace, building on a relationship forged with alcohol-free beer, wine and adult format beverage maker Hill Street Beverage Company Inc. (TSX.V: BEER) to present its DehydraTECH-licensed products to Canada’s licensed producers.

DehydraTECH is Lexaria’s patented platform for delivering ingestible substances in a rapid-effect manner that works with all psychoactive and non-psychoactive cannabinoids, nicotine, non-steroidal anti-inflammatory drugs (NSAIDs) and fat-soluble vitamins, whether in the form of foods, liquid emulsions, tablets or capsules (http://ibn.fm/Ope7W).

The brand formed in conjunction with Hill Street will feature processed tetrahydrocannabinol (THC) and/or cannabidiol (CBD) powder derived from cannabis or its less chemically psychoactive hemp variant.

Canada’s 2.0 regulations have been designed to sidestep some of the health concerns that have arisen in parts of the United States where cannabis edibles are manufactured, taking into particular account concerns about the potential for infused candies, which are currently popular, to appeal to children who may be less physically able to process cannabis substances than adults (http://ibn.fm/pY5kP).

Lexaria’s technological stance is that it “promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules … (than) other delivery methods for bioactive substances in widespread use today such as inhalational delivery through smoking.”

In an interview with Forbes (http://ibn.fm/uCoMP) earlier this year regarding DehydraTECH’s efforts to forge an alternative to smoking cigarettes for people with a nicotine addiction, CEO Chris Bunka noted some of his own personal motivation, stating, “Wherever there are many victims from past injustices, there is a lot of anger and resentment that doesn’t go away easily. My father also died from lung cancer just last year, so I am no fan.”

Lexaria’s non-combustion-based, non-inhalation-based delivery method requires no chemicals or additives.

“We use a patented dehydration synthesis process to combine the nicotine with simple ingredients like sunflower oil in a unique way,” Bunka told Forbes. “It allows for the removal of the bitter taste often associated with nicotine without the need for artificial flavors that are often appealing to children. Moreover, tested in animals in 2018, we proved that DehydraTECH could deliver nicotine to the bloodstream of an animal in as little as two minutes. The fact that it is fast means that smokers might not be frustrated waiting for their nicotine experience to begin, the way they have been with traditional nicotine products such as gums and lozenges.”

Lexaria’s subsidiary structure for managing licensing for differing molecular classes has not generated as much media buzz when it comes to NSAID pain relievers such as aspirin and ibuprofen, or for fat-soluble vitamins, but these common household remedies also have potential harmful digestion effects and time-intensive concerns that DehydraTECH’s delivery tech may be able to sidestep.

The company also announced recently that it received a new patent in Australia for potential pharmaceutical applications of its DehydraTECH for combatting ‘certain conditions’, including heart disease, neurological diseases including Parkinson’s, hepatic (liver) diseases and diabetes through the delivery of cannabinoids (http://ibn.fm/QOxfP).

Nicotine-containing edibles also showed the potential for reducing Parkinson’s disease risk during testing in 2013 (http://ibn.fm/faHXq), showing still further possibilities for Lexaria’s technology.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at  http://ibn.fm/LXRP